Treatment | Day of treatment or re-infestation | |||||||
---|---|---|---|---|---|---|---|---|
0 | 14 | 28 | 42 | 58 | 76 | 90 | ||
Placebo | Range | 18–32 | 3–17 | 7–23 | 3–27 | 6–28 | 7–27 | 7–25 |
A. mean | 24.1 | 10.5 | 15.1 | 14.3 | 18.4 | 14.5 | 17.3 | |
G. mean1 | 23.8a | 9.3a | 13.9a | 12.4a | 17.2a | 13.0a | 16.4a | |
Sarolaner | Range | 2–15 | 2–14 | 8–20 | 6–24 | 7–16 | 3–22 | 9–23 |
A. mean | 7.3 | 7.8 | 11.9 | 12.6 | 11.3 | 11.9 | 13.9 | |
Efficacy (%) | 69.9 | 26.2 | 21.5 | 11.4 | 38.8 | 18.1 | 19.6 | |
G. mean1 | 5.7c | 6.7a,b | 11.3a | 11.5a | 10.9a | 9.8a | 13.2a | |
Efficacy (%) | 76.0 | 27.5 | 18.3 | 7.5 | 36.6 | 24.6 | 19.0 | |
P-value vs placebo | < 0.0001 | 0.2624 | 0.4612 | 0.7786 | 0.0972 | 0.3085 | 0.4375 | |
Fluralaner | Range | 3–29 | 0–14 | 2–19 | 5–36 | 15–17 | 5–19 | 11–28 |
A. mean | 13.5 | 5.1 | 10.5 | 21.3 | 15.8 | 12.0 | 16.4 | |
Efficacy (%) | 44.0 | 51.2 | 30.6 | 0.0 | 14.3 | 17.2 | 5.1 | |
G. mean1 | 11.1b | 3.6b | 8.9a | 19.1a | 15.7a | 11.0a | 15.6a | |
Efficacy (%) | 53.4 | 61.4 | 35.9 | 0.0 | 8.7 | 15.6 | 4.8 | |
P-value vs placebo | 0.0038 | 0.0012 | 0.0966 | 0.1010 | 0.7241 | 0.5211 | 0.8494 | |
P-value vs sarolaner | 0.0440 | 0.0750 | 0.4523 | 0.1060 | 0.2476 | 0.7240 | 0.6037 |